Vivaglobin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Common Variable Immunodeficiency
Conditions
Common Variable Immunodeficiency, Agammaglobulinemia
Trial Timeline
Mar 1, 2007 โ Oct 1, 2008
NCT ID
NCT00520494About Vivaglobin
Vivaglobin is a approved stage product being developed by CSL for Common Variable Immunodeficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00520494. Target conditions include Common Variable Immunodeficiency, Agammaglobulinemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00701662 | Phase 2 | Completed |
| NCT00520494 | Approved | Completed |
Competing Products
20 competing products in Common Variable Immunodeficiency